Tax Management India. Com
Law and Practice  :  Digital eBook
Research is most exciting & rewarding
  TMI - Tax Management India. Com
Follow us:
  Facebook   Twitter   Linkedin   Telegram

TMI Blog

Home

Remlife Global Partners With JiyaYu Lifesciences To Replace Animal Inputs In APIs Via Green Chemistry

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... Remlife Global Partners With JiyaYu Lifesciences To Replace Animal Inputs In APIs Via Green Chemistry
PTI News
Dated:- 9-5-2025
PTI
A transformative alliance to eliminate animal-origin inputs in API production through innovative fermentation and biocatalysis. New Delhi [India], May 9: Remlife Global PTE LTD., a Singapore-based subsidiary of BSE-listed Remedium Lifecare Ltd. (India), .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... is pleased to announce a forward-looking partnership with JiyaYu Lifesciences PTE Ltd., a green chemistry technology platform company. This collaboration is focused on replacing animal-origin raw materials in the manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates through proprietary fermentation and biocatalyst-based alternatives. As part of the partnership, Jiy .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... aYu will license out fully developed and scalable technologies to Remlife Global on an exclusive basis. These technologies are designed to replace traditional animal-derived steps with sustainable, cost-effective, and regulatorycompliant bioprocesses. Remlife Global will scale up and commercialise these technologies at one or more GMP-compliant contract manufacturing sites across India, Singapore, .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... Malta, Ireland, Belgium, and Italy. JiyaYu Lifesciences has in turn partnered with a UK-based R&D technology platform specialising in the development of fermentation and biocatalystbased alternatives to animal-origin pharmaceutical inputs. Through this collaboration, JiyaYu gains access to cutting-edge innovations that it will transfer to Remlife Global as fully scalable technologies. Each te .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... chnology will be supported by detailed process dossiers and full technology transfer documents, enabling Remlife Global to implement, validate, and scale up the processes at approved GMP manufacturing sites. These solutions will support Remlife Global’s vision of eliminating dependence on vulnerable and ethically complex supply chains, while capturing new commercial opportunities in global regul .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... ated markets. “Our collaboration with JiyaYu Lifesciences is a transformative move toward building a more ethical, resilient, and sustainable pharmaceutical supply chain.” said Adarsh Munjal. Financial Outlook Each technology platform has a minimum commercial potential of ?50 crore per product, with EBITDA margins estimated between 20% to 25%. Assuming a scale-up of two products per year, cumu .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... lative revenue and EBITDA could grow substantially: • FY26: 2 products | ?100 Cr revenue | ?20–25 Cr EBITDA • FY27: 4 products | ?200 Cr revenue | ?40–50 Cr EBITDA Moving Beyond Animal-Based Inputs Remlife Global’s strategic direction is anchored in the belief that the future of pharmaceuticals lies in sustainable, animal-free production. Key reasons for this shift include: • Ethical and ESG Align .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... ment: Modern pharmaceutical companies are under growing pressure to remove animal-based components from their supply chains. • Safety & Quality Control: Fermentation and biocatalyst-based systems offer superior consistency and eliminate the risk of contamination from animal-borne pathogens. • Supply Chain Resilience: Diseases, regulatory shifts, and geopolitical volatility all threaten the ava .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... ilability of animal-derived inputs. • Environmental Benefits: Traditional animal-derived raw materials are linked to high emissions, land use, and water consumption. • Industry Momentum: Leading global pharma firms are rapidly adopting bio-based and cruelty-free technologies in their development pipelines. About Remlife Global PTE LTD. Remlife Global PTE LTD. is the international innovatio .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... n arm of Remedium Lifecare Ltd. (India), a BSE-listed pharmaceutical company. With a focus on R&D commercialisation and strategic collaborations, Remlife Global is driving the transition to sustainable API Contract manufacturing across multiple global jurisdictions. Media Contact Adarsh Munjal Remlife Global PTE LTD. Email: [email protected] (Disclaimer: The above press release comes to you unde .....

X X   X X   Extracts   X X   X X

→ Full Text of the Document

X X   X X   Extracts   X X   X X

..... r an arrangement with PNN and PTI takes no editorial responsibility for the same.). PTI PWR PWR
News - Press release - PIB

 

 

 

 

Quick Updates:Latest Updates